Billiontoone (NASDAQ:BLLN) Earns Buy Rating from Guggenheim

Billiontoone (NASDAQ:BLLN)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a note issued to investors on Thursday,Benzinga reports. They presently have a $120.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 48.46% from the stock’s previous close.

Other analysts have also issued reports about the company. Weiss Ratings began coverage on Billiontoone in a report on Tuesday, February 3rd. They set a “sell (d)” rating on the stock. Jefferies Financial Group began coverage on shares of Billiontoone in a research note on Monday, December 1st. They set a “hold” rating and a $117.00 price objective on the stock. JPMorgan Chase & Co. dropped their target price on shares of Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, December 10th. Wall Street Zen raised shares of Billiontoone to a “hold” rating in a report on Saturday, November 15th. Finally, Wells Fargo & Company began coverage on shares of Billiontoone in a research note on Monday, December 1st. They issued an “equal weight” rating and a $110.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $132.43.

Billiontoone Price Performance

Shares of Billiontoone stock opened at $80.83 on Thursday. The firm has a market cap of $3.70 billion and a PE ratio of 808.30. Billiontoone has a twelve month low of $66.00 and a twelve month high of $138.70. The business has a 50-day simple moving average of $86.15.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, March 4th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.04 by $0.07. The business had revenue of $96.05 million for the quarter, compared to the consensus estimate of $85.85 million. The firm’s revenue was up 113.0% compared to the same quarter last year.

Institutional Trading of Billiontoone

Hedge funds have recently added to or reduced their stakes in the stock. Adams Street Partners LLC acquired a new position in shares of Billiontoone during the fourth quarter worth $140,063,000. Baillie Gifford & Co. bought a new stake in Billiontoone during the 4th quarter worth $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone in the 4th quarter worth about $39,717,000. JPMorgan Chase & Co. bought a new position in Billiontoone in the fourth quarter valued at about $32,078,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Billiontoone in the fourth quarter valued at about $18,631,000.

Key Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q4 results beat expectations — BillionToOne reported $0.11 EPS vs. $0.04 consensus and revenue of $96.05M vs. $85.85M expected; revenue was up 113% year-over-year, signaling strong execution and growth. Read More.
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $430M–$445M versus a $356M Street consensus — this aggressive top‑line outlook is a primary reason investors are bidding the stock higher. Read More.
• Positive Sentiment: Earnings call highlights emphasize record revenue growth and strategic initiatives (product/market expansion) that support the raised guidance and growth trajectory. Read More.
• Neutral Sentiment: BTIG trimmed its price target from $160 to $140 but maintained a “Buy” rating — that keeps institutional endorsement in place while slightly lowering upside expectations vs prior coverage. Read More.
• Neutral Sentiment: Analyst/coverage writeups (Zacks, local snapshot) provide context and metric comparisons but do not materially change the story: beats + raised guidance remain the primary drivers. Read More. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feeds are garbled (zero/NaN), so there’s no reliable short‑interest signal to interpret from those entries today. (No actionable link — data appears erroneous.)

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.